A5003278567- Pregnancy and Medication Impact
- Reproductive System and Pregnancy
- Eosinophilic Esophagitis
- Inflammatory Bowel Disease
- Microscopic Colitis
- Pharmaceutical studies and practices
- Adolescent and Pediatric Healthcare
- Acute Lymphoblastic Leukemia research
- Systemic Lupus Erythematosus Research
- Immunodeficiency and Autoimmune Disorders
- Health Systems, Economic Evaluations, Quality of Life
- COVID-19 Impact on Reproduction
- Endometriosis Research and Treatment
- Pregnancy and preeclampsia studies
- Diabetes and associated disorders
- Helicobacter pylori-related gastroenterology studies
- Genetic factors in colorectal cancer
- Gastrointestinal motility and disorders
- Infant Nutrition and Health
- Renal Transplantation Outcomes and Treatments
- Renal Diseases and Glomerulopathies
- Celiac Disease Research and Management
- Breastfeeding Practices and Influences
- Maternal Mental Health During Pregnancy and Postpartum
- Liver Diseases and Immunity
Aarhus University Hospital
2015-2025
Aarhus University
2007-2025
Aalborg University
2022-2024
Predict (France)
2024
St Vincent's Hospital
2012-2022
The University of Melbourne
2012-2022
Regional Hospital Horsens
2017-2019
Human Factors (Norway)
2019
Technical University of Munich
2015
Inflammatory bowel disease has a high incidence and prevalence especially in young individuals their reproductive years. Trying to conceive being pregnant is an emotional period for those involved. In the majority of patients suffering from inflammatory disease, maintenance therapy required during pregnancy control might necessitate introduction new drugs vulnerable period. Therefore, management with wish requires specialized counselling appropriate including multidisciplinary approach close...
The long-term safety of exposure to anti-tumor necrosis factor (anti-TNFα) drugs during pregnancy has received little attention. We aimed compare the relative risk severe infections in children mothers with inflammatory bowel disease (IBD) who were exposed anti-TNFα utero that not drugs.Retrospective multicenter cohort study. Exposed cohort: from IBD receiving medication (with or without thiopurines) at any time 3 months before conception. Non-exposed treated agents thiopurines cumulative...
Summary Background Women with inflammatory bowel diseases (IBD) often receive biologicals during pregnancy to maintain disease remission. Data on outcome of vedolizumab‐exposed pregnancies (VDZE) are sparse. Aims To assess and child outcomes VDZE compare these results anti‐TNF exposed (TNFE) or both immunomodulatory biologic unexposed (CON IBD) pregnancies. Methods A retrospective multicentre case‐control observational study was performed. Results group included 79 in 73 IBD women. The TNFE...
Summary Background The advent of new therapeutic agents and the improvement supporting care might change management acute severe ulcerative colitis (ASUC) avoid colectomy. Aims To evaluate colectomy‐free survival safety a third‐line treatment in patients with ASUC refractory to intravenous steroids who failed either infliximab or ciclosporin. Methods Multicentre retrospective cohort study had ciclosporin received during same hospitalisation. Patients stopped second‐line due disease activity...
Adherence to medical treatment among women with ulcerative colitis (UC) prior and during pregnancy has never been investigated. The aim was examine predictors for prevalence rates of nonadherence maintenance UC pregnancy.We identified 115 having given birth 2000-2005 within a population 1.6 million. They received questionnaire about adherence relapses were registered. We retrieved information on from prescription databases used logistic regression estimate odds ratios (POR) by different...
Summary Background Anti‐tumor necrosis factor‐α ( TNF ‐α) is used for the treatment of severe cases IBD , including Crohn's disease CD ) and ulcerative colitis UC ). However, one‐third patients do not respond to treatment. We have previously investigated whether single nucleotide polymorphisms SNP s) in genes involved inflammation were associated with response anti‐ therapy among or . Aim A new cohort was established replication previous findings identify s response. Methods Fifty‐three...
Noninvasive biomarkers of inflammation for monitoring inflammatory bowel disease (IBD) are important in pregnancy. Clinical and laboratory markers often affected by the physiological adaption that occurs during pregnancy, although, few, if any, data exist on fecal calprotectin (FC). We investigated FC concentrations pregnant controls IBD women, whether correlated with physician global assessment (PGA), C-reactive protein (CRP), Harvey-Bradshaw Index (HBI)/Simple Colitis Activity (SCCAI)...
Evidence on ustekinumab safety in pregnancy is gradually expanding, but its clearance the postnatal period unknown. The aim of this study was to investigate concentrations umbilical cord blood and rates after birth, as well how these correlate with maternal drug concentrations, risk infection, developmental milestones during first year life.
Abstract Background A core outcome set (COS) for patients with inflammatory bowel disease (IBD) was recently developed through a multi-stakeholder consensus in the Health Outcomes Observatory (H2O) project.(1) Recognizing importance of data visualisation enhancing management, H2O website now provides population-level dashboard to track quality and key performance indicators.(2) Patient-level dashboards are designed support both healthcare providers (HCPs) by facilitating individual health...
Abstract Background The pharmacokinetic (PK) profile of vedolizumab during pregnancy is not fully characterised, though concentrations have been reported to drop1.To minimise transplacental transfer, discontinuation in the 3rd trimester has suggested, but this may lead flare IBD and postpartum2. This study aimed characterise changes PK using mathematical modelling explore dosing scenarios guide decisions on 3rd-trimester dosing. Methods A multicenter, prospective, observational was conducted...
Abstract Background Food-related quality of life (FRQoL) is the enjoyment experienced from psychosocial aspects eating and drinking. FRQoL may be altered in patients with inflammatory bowel disease (IBD). Meanwhile, often change their diet following diagnosis. We aimed to describe dietary choices IBD using validated questionnaires identify potential predictors impaired FRQoL. Methods This was a cross-sectional, single-centre survey. The FR-QoL-291 belief2 were forward-backwards translated...
Aliment Pharmacol Ther 2010; 32: 49–58 Summary Background Adherence to medical treatment among women with Crohn’s disease (CD) prior and during pregnancy has never been reported. Aim To examine both the predictors prevalence rates of non‐adherence maintenance CD Methods Among a population 1.6 million inhabitants, we identified total 132 who had given birth 2000–2005. Questionnaires were used investigate extent adherence. The validity self‐reported use medication was assessed using data from...
Summary Background Little is known about the consequences of intrauterine exposure to, and post‐natal clearance of, vedolizumab. Aims To investigate levels vedolizumab in umbilical cord blood newborns rates after birth, as well how these correlated with maternal drug levels, risk infection developmental milestones during first year life Methods Vedolizumab‐treated pregnant women inflammatory bowel disease were prospectively recruited from 12 hospitals Denmark Canada 2016‐2020. Demographics...
Summary Background and Aims Inflammatory bowel disease (IBD) activity during pregnancy is associated with adverse outcomes. We aimed to identify key clinical characteristics that predict pregnancy. Methods Between January 2008 through 2021, we identified all singleton pregnancies among women IBD recorded in patient birth registries at a tertiary centre Denmark. Maternal infant data were retrieved from medical records. Demographics, Physicians Global Assessment (PGA) of 6 months prior three...
Objectives. Adherence to medical treatment among women with Crohn's disease (CD) in the postpartum period has never been examined. The impact of breast-feeding on activity remains controversial. We aimed assess rates non-adherence CD period. Further, and risk relapse. Methods. Within a population 1.6 million, we identified 154 who had given birth within 6-year combined questionnaire data, data from records public register data. used logistic regression estimate prevalence odds ratios (POR)...
Women with inflammatory bowel disease (IBD) may have decreased sexual function. To understand how common this condition is in our female patients, we developed a new IBD-specific Female Sexual Dysfunction Scale (the IBD-FSDS). We performed prospective cross-sectional study of 454 IBD patients ≥18 years age attending 1 3 clinics the United States or Denmark. gathered information on function via de novo 23-item scale. General functioning was measured Function Index (FSFI) and Distress...
Objective In utero exposure to maternal inflammation may impact immune system development and subsequent risk of disease. We investigated whether a diagnosis IBD before childbirth is linked higher in offspring compared with after childbirth. Further, we analysed paternal status for comparison. Design Using Danish health registers, identified all individuals born Denmark between 1997 2022 their legal parents, as well status. Cox proportional hazards regression analyses adjusted calendar...
Objective: In inflammatory bowel disease (IBD), adherence to both medical treatment and other aspects of care has a substantial impact on the course disease. Most studies have reported that 30–45% patients with IBD were non-adherent. Our study aimed investigate different identify predictors non-adherence, including quality care, for outpatients IBD.Materials methods: An anonymous electronic questionnaire was used adherence, patient involvement shared decision making among 377...
Discontinuation of anti-TNF before gestational week 30 did not increase the risk relapse in third trimester. Relapse and continuation throughout pregnancy were each independently associated with lower birth weight, a marker long-term adverse outcomes.